It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Olfactory ensheathing cells (OECs) are crucial for promoting the regeneration of the primary olfactory nervous system that occurs throughout life. Transplantation of OECs has emerged as a promising therapy for nervous system injuries, in particular for spinal cord injury repair. Functional outcomes in both animals and humans are, however, highly variable, primarily because it is difficult to rapidly obtain enough OECs for transplantation. Compounds which can stimulate OEC proliferation without changing the phenotype of the cells are therefore highly sought after. Additionally, compounds which can stimulate favourable cell behaviours such as migration and phagocytic activity are desirable. We conducted a medium-throughput screen testing the Davis open access natural product-based library (472 compounds) and subsequently identified the known plant natural product 2-methoxy-1,4-naphthoquinone as a stimulant of OEC viability. We showed that 2-methoxy-1,4-naphthoquinone: (i) strongly stimulates proliferation over several weeks in culture whilst maintaining the OEC phenotype; (ii) stimulates the phagocytic activity of OECs, and (iii) modulates the cell cycle. We also identified the transcription factor Nrf2 as the compound’s potential molecular target. From these extensive investigations we conclude that 2-methoxy-1,4-naphthoquinone may enhance the therapeutic potential of OECs by stimulating proliferation prior to transplantation.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Clem Jones Centre for Neurobiology and Stem Cell Research, Griffith University, Nathan, Australia (GRID:grid.1022.1) (ISNI:0000 0004 0437 5432); Griffith Institute for Drug Discovery, Griffith University, Nathan, Australia (GRID:grid.1022.1) (ISNI:0000 0004 0437 5432); Menzies Health Institute Queensland, Griffith University, Southport, Australia (GRID:grid.1022.1) (ISNI:0000 0004 0437 5432)
2 Clem Jones Centre for Neurobiology and Stem Cell Research, Griffith University, Nathan, Australia (GRID:grid.1022.1) (ISNI:0000 0004 0437 5432); Menzies Health Institute Queensland, Griffith University, Southport, Australia (GRID:grid.1022.1) (ISNI:0000 0004 0437 5432)
3 Griffith Institute for Drug Discovery, Griffith University, Nathan, Australia (GRID:grid.1022.1) (ISNI:0000 0004 0437 5432)